CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
The CART30 therapy, targeting CD30-positive Hodgkin's and Non-Hodgkin's lymphomas, represents a significant advancement in CAR T-cell therapy, particularly for patients with relapsed or refractory disease. The market for CAR T-cell therapies is expanding rapidly, with increasing demand for innovative treatments in hematological malignancies. Given the limited options for patients who have undergone autologous stem-cell transplantation or are refractory to standard therapies, CART30 could capture a substantial share of this niche market. Competitive analysis indicates that while several CAR T therapies are in development, the specificity for CD30 may provide a unique selling proposition. Diligence should focus on regulatory pathways, potential partnerships, and reimbursement strategies in the Chinese market and beyond.
Indication: Hodgkin's Lymphoma
Modality: protein therapy
Target: CD30-positive lymphomas
Sponsor: Chinese PLA General Hospital
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CD30-positive lymphomas
View original source fields
Condition raw: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Condition normalized: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: CD30-positive lymphomas
Target normalized: CD30-positive lymphomas